BioCentury
ARTICLE | Clinical News

IM862: Began Phase III trial

July 24, 2000 7:00 AM UTC

Cytran Inc., Kirkland, Wash. Product: IM862 Business: Cancer Therapeutic category: Angiogenesis Target: Unknown Description: Naturally occurring peptide consisting of two amino acids (glutamyl tryptop...